{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:adegramotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00996255: Phase 1 Interventional Terminated Advanced/Metastatic Solid Tumors
(2006)
Source URL:
Class:
PROTEIN
Targets:
Conditions:
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 uM. In colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 uM indicating that it has efficient and prolonged antiproliferative activity. PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation. PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
Status:
Investigational
Source:
NCT02966509: Not Applicable Interventional Completed End of Life
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:naratuximab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02219724: Phase 1 Interventional Completed Neoplasms
(2014)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03703102: Phase 2 Interventional Completed Atopic Dermatitis
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03703505: Phase 1 Interventional Completed Healthy Volunteers
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03388593: Phase 3 Interventional Recruiting Chronic Heart Failure
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00418795: Phase 2/Phase 3 Interventional Completed Acute Intermittent Porphyria
(2003)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01097096: Phase 2 Interventional Completed Alzheimer's Disease
(2010)
Source URL:
Class:
PROTEIN
